Journal
IMMUNITY
Volume 36, Issue 4, Pages 646-657Publisher
CELL PRESS
DOI: 10.1016/j.immuni.2012.03.009
Keywords
-
Categories
Funding
- National Health and Medical Research Council of Australia (NHMRC) [454465, 461219, 461221, 575546, 1009145]
- Human Frontier Science Program
- Australian Research Council
- NHMRC
- Australian Cancer Research Foundation
- Leukemia & Lymphoma Society [SCOR 7413]
- Melbourne University
- Cancer Council
Ask authors/readers for more resources
The immune system must distinguish viable cells from cells damaged by physical and infective processes. The damaged cell-recognition molecule Clec9A is expressed on the surface of the mouse and human dendritic cell subsets specialized for the uptake and processing of material from dead cells. Clec9A recognizes a conserved component within nucleated and nonnucleated cells, exposed when cell membranes are damaged. We have identified this Clec9A ligand as a filamentous form of actin in association with particular actin-binding domains of cytoskeletal proteins. We have determined the crystal structure of the human CLEC9A C-type lectin domain and propose a functional dimeric structure with conserved tryptophans in the ligand recognition site. Mutation of these residues ablated CLEC9A binding to damaged cells and to the isolated ligand complexes. We propose that Clec9A provides targeted recruitment of the adaptive immune system during infection and can also be utilized to enhance immune responses generated by vaccines.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available